Firocoxib (Previcox) Side Effects in Dogs: What 7,988 FDA Reports Show
FDA adverse-event reports for firocoxib (Previcox) in dogs: 7,988 canine reports analyzed, kidney vs liver markers, clinical trials vs field data, and 2023 generics.
Firocoxib is a second-generation, highly selective cyclooxygenase-2 (COX-2) inhibiting nonsteroidal anti-inflammatory drug (NSAID) widely prescribed in veterinary medicine to manage pain and inflammation associated with canine osteoarthritis and orthopedic or soft-tissue surgery. First approved by the United States Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) under New Animal Drug Application (NADA) 141-230 on July 21, 2004, the drug was originally commercialized under the proprietary brand name Previcox (originally Merial, now marketed by Boehringer Ingelheim Animal Health). For nearly two decades, Previcox stood alongside carprofen and meloxicam as one of the primary mainstays of canine chronic pain management.
For dog owners and veterinary teams, firocoxib represents an intriguing therapeutic option. In vitro and ex vivo canine assays demonstrate that firocoxib possesses approximately 380-fold selectivity for the inducible COX-2 isoenzyme (responsible for inflammatory prostanoids) over the constitutive COX-1 isoenzyme (which supports gastric mucosal cytoprotection and normal renal blood flow). However, COX-2 selectivity does not confer absolute safety. In the real world, dogs receiving daily NSAID therapy can experience gastrointestinal ulceration, renal compromise, hepatic enzyme shifts, or treatment failure.
In the federal adverse-event registry maintained by the FDA CVM—covering spontaneous post-marketing pharmacovigilance reports submitted through mid-2026—firocoxib is named in 9,545 unique adverse-event records across all species, with 7,988 reports specifically involving dogs. (In a class-level overview of veterinary NSAID adverse-event reports in the FDA database, firocoxib was listed with 7,670 reports; that overview utilized an exact-token match on an earlier snapshot, whereas this dedicated deep dive captures strength-variant ingredient tokens across the updated extract, accounting for the higher total.)
To provide clinicians, veterinary technicians, and pet owners with an objective, data-driven analysis, VetMedGuide recomputed and evaluated every firocoxib report in the federal database. Below is what the numbers actually reveal regarding gastrointestinal reaction frequencies, renal versus hepatic biomarkers, fatal outcome tallies in senior dogs, clinical trial data versus post-marketing reality, and the bioequivalence of generic chewable tablets approved since 2022.
Fast answer: What the FDA adverse-event data shows
Across 9,545 unique spontaneous adverse-event reports naming firocoxib in the FDA CVM database through July 2026:
- Species distribution: Dogs account for 7,988 reports (83.7% of all reports and 93.2% of the reports that record a species), horses account for 486 reports (5.1%, associated with equine firocoxib products such as the paste formulation Equioxx), cats account for 52 reports (0.5%, reflecting off-label exposure), and 975 records do not specify a species.
- Single-drug clean subset: Because multi-drug reports capture adverse reactions that may stem from concurrent medications, our reaction analysis focuses on the 4,387 single-drug canine reports (where firocoxib was the sole reported substance). In this clean cohort, vomiting is the leading reaction, appearing in 1,333 reports (30.4%), followed by anorexia (loss of appetite) in 656 reports (15.0%), diarrhea in 522 reports (11.9%), and elevated blood urea nitrogen (BUN) in 522 reports (11.9%).
- Renal markers lead over hepatic injury: Elevated kidney values (BUN in 522 single-drug reports and creatinine in 376 reports, or 8.6%) appear substantially more often in firocoxib reports than overt hepatic failure terms. While elevated liver enzymes appear (serum alkaline phosphatase / SAP in 407 reports and alanine aminotransferase / ALT in 356 reports), the clinical presentation skews toward renal azotemia rather than acute hepatic necrosis—a key contrast with the historical reputation of carprofen.
- Senior dog demographics and fatal outcomes: Fatal outcomes appear in 1,511 canine reports (1,242 coded as
Diedand 269 coded asEuthanized, totaling 18.9% of the 7,988 dog reports). Critically, 4,779 of the 7,332 dog reports with a recorded age (65.2%) involve dogs aged 8 years or older, with a median recorded body weight of 29 kg (64 lbs). In a senior population with multi-organ comorbidities receiving chronic pain therapy, mortality in passive reporting reflects background aging and terminal chronic illness rather than intrinsic drug toxicity. - Clinical trials vs. field surveillance: In pre-approval FDA field trials (NADA 141-230 Table 5), vomiting occurred in only 3.9% of firocoxib-treated dogs (5 of 128) versus 6.6% of active-control dogs (8 of 121), and diarrhea in 0.8% (1 of 128) versus 8.3% of controls.
- Generic availability: Since 2022, FDA-approved generic firocoxib chewable tablets have entered the US market: Firox (Norbrook, ANADA 200-722, approved March 28, 2022), Pegasus Laboratories generic (ANADA 200-751, approved June 22, 2023), and two generics approved August 3, 2023 — Felix Pharmaceuticals firocoxib (ANADA 200-755) and Firodyl (Ceva, ANADA 200-756). All four are bioequivalent to brand Previcox under FDA standards.
| Metric / Parameter | FDA Database Aggregate Value | Clinical Context & Interpretation |
|---|---|---|
| Total Unique Adverse Reports | 9,545 | Lifetime public extraction through July 2026 across all firocoxib formulations. |
| Canine Reports | 7,988 (83.7% total; 93.2% species-identified) | Primary target species for Previcox and generic chewable tablets. |
| Single-Drug Canine Subset | 4,387 reports | Clean analytical subset excluding confounding multi-drug polypharmacy. |
| Leading Single-Drug Reaction | Vomiting (1,333 mentions; 30.4%) | Upper GI irritation; primary clinical trigger to stop the drug and contact a clinic. |
| Elevated BUN (Kidney Marker) | 522 mentions (11.9% of single-drug dogs) | Renal azotemia signal; reinforces need for pre-treatment baseline and periodic panels. |
| Elevated Creatinine | 376 mentions (8.6% of single-drug dogs) | Parallel renal biomarker confirming functional filtration changes in vulnerable dogs. |
| Elevated SAP (Liver / Bone Enzyme) | 407 mentions (9.3% of single-drug dogs) | Often reflects background age-related or vacuolar hepatopathy in senior dogs. |
| Elevated ALT (Liver Enzyme) | 356 mentions (8.1% of single-drug dogs) | Hepatocellular leakage enzyme elevation. |
| Canine Fatal Outcomes | 1,511 reports (18.9% of 7,988 dog reports) | 1,242 Died and 269 Euthanized; concentrates heavily in geriatric dogs (65.2% of age-recorded reports are age 8+). |
| Median Patient Weight | 29.0 kg (63.9 lbs) | Reflects osteoarthritis prevalence in medium-to-large canine breeds. |
| Ineffective Analgesia (LOE) | 238 mentions (5.4% of single-drug dogs) | Treatment failure or disease progression requiring multimodal escalation. |
| Administration Route | Oral: 4,286 of 4,387 single-drug reports (97.7%) | Matches flavored chewable tablet dosage forms administered at home. |
Important context on passive surveillance: The FDA CVM adverse-event reporting system is a spontaneous passive pharmacovigilance repository. Reports are submitted voluntarily by veterinarians, pet owners, and manufacturers. The presence of a report demonstrates temporal association, not medical causation, and because the total number of treated dogs (the denominator) is unknown, adverse-event counts cannot be interpreted as incidence rates. For guidance on how to interpret these federal archives, see our methodology guide on how to read FDA animal drug adverse-event reports.
What is firocoxib, and which products contain it?
Firocoxib is a member of the coxib class of nonsteroidal anti-inflammatory drugs. It functions by selectively binding to the active site of the cyclooxygenase-2 enzyme, inhibiting the conversion of arachidonic acid into pro-inflammatory prostaglandins (particularly prostaglandin E2, or PGE2), thereby alleviating peripheral joint pain, synovial swelling, and lameness.
In the United States, firocoxib is manufactured and distributed under several FDA-approved veterinary applications:
- Previcox Chewable Tablets (NADA 141-230): The original pioneer drug approved in July 2004, supplied in 57 mg and 227 mg scored, flavored chewable tablets for once-daily oral administration in dogs.
- Firox Chewable Tablets (ANADA 200-722): Approved on March 28, 2022 (sponsored by Norbrook Laboratories), establishing the first FDA-approved generic equivalent.
- Firocoxib Chewable Tablets for Dogs (ANADA 200-751): Approved on June 22, 2023 (sponsored by Pegasus Laboratories, the affiliate of PRN Pharmacal).
- Firocoxib Chewable Tablets (ANADA 200-755): Approved on August 3, 2023 (sponsored by Felix Pharmaceuticals).
- Firodyl Chewable Tablets (ANADA 200-756): Approved on August 3, 2023 (sponsored by Ceva Sante Animale).
- Equioxx (NADA 141-253 / NADA 141-313): Equine-specific oral paste and injectable formulations approved strictly for horses to manage osteoarthritis pain. The 486 equine reports in the federal database cover these horse products; see our separate analysis of equine drug adverse-event reports. Equine products must never be administered to dogs.
The labeled dosage for dogs across all approved oral formulations is 5.0 mg/kg (2.27 mg/lb) body weight once daily as needed, with or without food.
What do the FDA adverse-event reports actually show for dogs?
When evaluating the 4,387 single-drug canine adverse-event reports in the FDA CVM database, clinical signs cluster into three distinct organ systems: gastrointestinal, renal, and systemic/neurological.
| Adverse Reaction Coding Token | Number of Single-Drug Dog Reports | Share of Single-Drug Dog Reports | Clinical Mechanism & Organ System |
|---|---|---|---|
| Vomiting | 1,333 | 30.4% | Gastric mucosal irritation; altered local prostaglandin synthesis. |
| Anorexia (Loss of Appetite) | 656 | 15.0% | Nausea, gastric discomfort, or early systemic malaise. |
| Diarrhea | 522 | 11.9% | Altered intestinal fluid dynamics and mucosal permeability. |
| Elevated Blood Urea Nitrogen (BUN) | 522 | 11.9% | Renal hypoperfusion, prerenal dehydration, or intrinsic nephron injury. |
| Elevated Serum Alkaline Phosphatase (SAP) | 407 | 9.3% | Hepatic canalicular enzyme elevation; background geriatric changes. |
| Death (Spontaneous) | 389 | 8.9% | Unclassified terminal event in senior comorbid patients. |
| Elevated Creatinine | 376 | 8.6% | Direct marker of decreased glomerular filtration rate (GFR). |
| Depression / Lethargy | 372 | 8.5% | Systemic malaise, weakness, or nausea. |
| Elevated Alanine Aminotransferase (ALT) | 356 | 8.1% | Hepatocellular leakage enzyme elevation. |
| Death by Euthanasia | 345 | 7.9% | End-stage quality-of-life decision due to arthritis or comorbidity. |
| Ineffective Analgesia | 238 | 5.4% | Inadequate pain control or advancing joint degeneration. |
| Anaemia NOS | 204 | 4.6% | Gastrointestinal blood loss (ulceration) or chronic kidney disease. |
| Ataxia (Incoordination) | 190 | 4.3% | Neuromuscular weakness, severe pain, or systemic hypotension. |
| Bloody Diarrhea (Hematochezia / Melena) | 171 | 3.9% | Overt gastrointestinal ulceration or lower bowel hemorrhage. |
| Polydipsia (Increased Thirst) | 167 | 3.8% | Compensatory drinking secondary to renal concentrating deficit. |
| Polyuria (Increased Urination) | 76 | 1.7% | Impaired renal tubular water resorption. |
Firocoxib Single-Drug Adverse Reactions in Dogs (n = 4,387)
─────────────────────────────────────────────────────────────────
Vomiting [30.4%] ████████████████████ 1,333
Anorexia (Appetite Loss) [15.0%] ██████████ 656
Diarrhea [11.9%] ████████ 522
Elevated BUN (Kidney) [11.9%] ████████ 522
Elevated SAP (Liver/Bone) [ 9.3%] ██████ 407
Elevated Creatinine (Kidney)[8.6%] ██████ 376
Depression / Lethargy [ 8.5%] ██████ 372
Elevated ALT (Liver) [ 8.1%] █████ 356
Ineffective Analgesia [ 5.4%] ████ 238
Anaemia NOS [ 4.6%] ███ 204
Ataxia (Incoordination) [ 4.3%] ███ 190
Bloody Diarrhea [ 3.9%] ███ 171
─────────────────────────────────────────────────────────────────
Reporter source mix
Of the 4,387 single-drug canine cases, 808 were submitted by veterinarians, 338 by animal owners, and 3,241 by corporate marketing authorization holders or other reporting entities. Oral administration was confirmed in 4,286 reports (97.7%), consistent with daily tablet use in outpatient settings.
Why does firocoxib's report profile look more kidney than liver?
One of the most consequential clinical insights revealed by the FDA reporting data is the prominent representation of renal biomarkers relative to hepatic failure terms.
The physiological role of renal COX-2 in canines
In healthy canine kidneys, both COX-1 and COX-2 isoenzymes are constitutively expressed:
- COX-2 in the macula densa and thick ascending limb: COX-2-derived prostanoids (PGE2 and prostacyclin / PGI2) regulate renal renin release, maintain medullary blood flow, and modulate tubular sodium and water reabsorption.
- Autoregulatory response to hypoperfusion: When a dog experiences dehydration, anesthesia, heart disease, or concurrent diuretic therapy (e.g., furosemide), the renin-angiotensin-aldosterone system causes renal vasoconstriction. In response, local COX-2 prostanoids dilate the afferent arterioles to preserve glomerular filtration rate.
- Impact of COX-2 inhibition: By blocking COX-2, firocoxib prevents this protective vasodilation. In a volume-depleted or senior patient, renal blood flow drops, precipitating prerenal azotemia or acute tubular ischemia.
This physiological mechanism explains why elevated BUN (522 mentions) and elevated creatinine (376 mentions) appear so prominently in the single-drug dataset. Furthermore, clinical signs of renal decompensation—such as increased thirst (polydipsia, 167 mentions) and increased urination (polyuria, 76 mentions)—frequently accompany these laboratory shifts.
Comparing firocoxib and carprofen reporting patterns
In veterinary pharmacovigilance, different NSAIDs exhibit distinct reporting tendencies:
- Carprofen (Rimadyl): Historically recognized for rare, idiosyncratic hepatocellular necrosis (acute toxic hepatitis), typically occurring within the first 14 to 28 days of therapy in young-to-middle-aged dogs (with historical overrepresentation in Labrador Retrievers). For details, review our analysis of carprofen (Rimadyl) side effects and FDA reports.
- Firocoxib (Previcox): While hepatic enzyme elevations appear (SAP 407, ALT 356), severe clinical liver failure is rarely reported. Instead, the real-world safety signal is dominated by upper gastrointestinal upset and renal azotemia in geriatric patients with pre-existing or borderline subclinical renal compromise.
This does not mean firocoxib is toxic to kidneys or that carprofen is toxic to livers; rather, it highlights that pre-treatment bloodwork for firocoxib must include a careful evaluation of renal parameters (BUN, creatinine, SDMA, and urine specific gravity) before initiating therapy.
How do the field reports compare with the drug's clinical trials?
When evaluating drug safety, comparing pre-approval randomized controlled clinical trials against post-marketing passive surveillance provides essential context.
In the original FDA Freedom of Information (FOI) Summary for NADA 141-230, Table 5 documents adverse reactions observed during multi-center US field trials in 249 client-owned dogs treated for osteoarthritis for 30 days:
| Adverse Reaction Category | Firocoxib Field Trial Group (n = 128) | Active-Control NSAID Group (n = 121) | FDA Spontaneous Database Share (Single-Drug Dogs, n = 4,387) |
|---|---|---|---|
| Vomiting | 5 dogs (3.9%) | 8 dogs (6.6%) | 1,333 dogs (30.4%) |
| Diarrhea | 1 dog (0.8%) | 10 dogs (8.3%) | 522 dogs (11.9%) |
| Decreased Appetite / Anorexia | 3 dogs (2.3%) | 3 dogs (2.5%) | 656 dogs (15.0%) |
| Lethargy / Depression | 1 dog (0.8%) | 3 dogs (2.5%) | 372 dogs (8.5%) |
| Weight Loss | 3 dogs (2.3%) | 0 dogs (0.0%) | Unclassified / Low |
| Sluggishness / Inactivity | 1 dog (0.8%) | 1 dog (0.8%) | Captured under lethargy |
Why post-marketing numbers run higher than trial percentages
The marked divergence between controlled trial rates (3.9% vomiting) and post-marketing reporting shares (30.4% vomiting) illustrates two fundamental realities of veterinary medicine:
- Trial Selection Criteria: Pre-approval field trials strictly exclude dogs with concurrent renal disease, liver dysfunction, heart failure, gastrointestinal disease, or polypharmacy. In the real world, firocoxib is prescribed to elderly dogs with multiple subclinical conditions.
- Reporting Filter: Pet owners and clinics rarely submit an adverse-event report when a dog does well on a medication. The database captures only patients that experienced an event, so vomiting naturally constitutes a large percentage of reported complaints.
- Independent Evidence: In a peer-reviewed controlled safety study evaluating oral firocoxib in healthy dogs (published in PMC7194286), the drug demonstrated excellent gastric mucosal and biochemical tolerability at labeled doses over 28 days. Similarly, a 90-day geriatric canine study (PubMed 20169752) confirmed that senior dogs maintained stable renal and hepatic function when monitored with routine blood chemistry.
Which dogs should not take firocoxib?
Like all veterinary NSAIDs, firocoxib carries specific contraindications and safety boundaries established in FDA approval documentation and clinical pharmacology literature.
Absolute contraindications
- Concurrent NSAID therapy: Never administer firocoxib simultaneously with another NSAID (such as carprofen, meloxicam, deracoxib, or grapiprant). A minimum washout period (typically 5 to 7 days, or longer depending on the half-life of the prior agent) is required when switching between NSAIDs.
- Concurrent corticosteroid therapy: Co-administration with prednisone, prednisolone, dexamethasone, or triamcinolone dramatically amplifies the risk of severe, life-threatening gastrointestinal perforation and ulceration.
- Active gastrointestinal ulceration or bleeding: Dogs with active vomiting, hematemesis, or melena must not receive NSAIDs.
- Severe, decompensated renal or hepatic failure: Patients with end-stage renal failure (IRIS Stage 3 or 4) or severe hepatic cirrhosis cannot safely eliminate the drug or manage hemodynamic prostanoid shifts.
- Known hypersensitivity to firocoxib: Patients with prior allergic or idiosyncratic reactions.
Critical species and age restrictions
- Cats: Firocoxib is strictly contraindicated in cats. Feline species have deficient glucuronidation pathways and distinct renal COX physiology; exposure to canine doses can cause fatal acute renal necrosis and severe gastrointestinal hemorrhage. (The 52 feline reports in the FDA database represent accidental or off-label exposure.)
- Puppies and very small dogs: The current Previcox label warns that use at doses above the recommended dose in puppies less than seven months of age has been associated with serious adverse reactions, including death. In the juvenile safety study behind that warning (10-13-week-old Beagle puppies treated for six months), one puppy given 3X the labeled dose and three puppies given 5X were euthanized in moribund condition, one 5X puppy died, and thalamic vacuolization (microscopic brain lesions) appeared in 3 of 6 puppies at 3X and 5 of 12 at 5X. At the labeled 1X dose, the study found only subclinical periportal hepatic fatty change. Separately, because of tablet sizes and scoring, dogs weighing less than 7 lb (3.2 kg) cannot be accurately dosed — tell your veterinarian if your dog is under 7 months of age or under 7 pounds.
- Breeding, pregnant, or lactating dogs: Safety has not been established in canine reproductive populations.
Previcox or generic firocoxib: Does the cheaper one work the same?
Until 2022, dog owners needing firocoxib had only one choice: brand-name Previcox. Between March 2022 and August 2023, the FDA approved four generic firocoxib chewable formulations, expanding access and significantly reducing monthly medication costs.
| Product Brand Name | Application Type & NADA/ANADA Number | Sponsor / Manufacturer | Approval Date | Bioequivalence Trial Details |
|---|---|---|---|---|
| Previcox | Pioneer NADA 141-230 | Boehringer Ingelheim Animal Health | July 21, 2004 | Original safety, efficacy, and target animal studies. |
| Firox | Generic ANADA 200-722 | Norbrook Laboratories Ltd. | March 28, 2022 | Blood level bioequivalence established against 57 mg and 227 mg Previcox. |
| Firocoxib Chewable Tablets | Generic ANADA 200-751 | Pegasus Laboratories / PRN Pharmacal | June 22, 2023 | In vivo canine blood bioequivalence; identical Cmax and AUC profiles. |
| Firocoxib Chewable Tablets | Generic ANADA 200-755 | Felix Pharmaceuticals Pvt. Ltd. | August 3, 2023 | Bioequivalence to Previcox under the ANADA pathway. |
| Firodyl | Generic ANADA 200-756 | Ceva Sante Animale | August 3, 2023 | Demonstrated bioequivalence under 21 CFR 514 standards. |
Brand vs. Generic Firocoxib Approval Timeline
2004 (Jul) Previcox Approved (Pioneer NADA 141-230)
│
│ ~18 Years of Pioneer Exclusivity
▼
2022 (Mar) Firox Approved (First Generic ANADA 200-722)
2023 (Jun) Pegasus / PRN Generic Approved (ANADA 200-751)
2023 (Aug) Felix Generic (ANADA 200-755) + Firodyl (ANADA 200-756)
Understanding FDA bioequivalence standards
To obtain FDA approval under an Abbreviated New Animal Drug Application (ANADA), generic manufacturers must prove in vivo bioequivalence in dogs:
- Same active ingredient, strength, and dosage form: The generic tablet contains the exact same chemical molecule (firocoxib) in identical 57 mg or 227 mg strengths.
- Equivalent peak concentration (Cmax) and total absorption (AUC): Blood-level pharmacokinetic studies in dogs must show that the rate and extent of absorption fall within strict statistical confidence intervals (80% to 125%) of the pioneer brand.
- Same indications and safety warnings: Generic tablets carry the exact same labeled indications, contraindications, and monitoring recommendations as Previcox.
For pet owners managing chronic canine osteoarthritis, FDA-approved generic firocoxib delivers the same active molecule at the same strengths, typically at meaningfully lower cost than brand Previcox. Switching between brand and generic does not require a medication washout period.
What monitoring should a dog on long-term firocoxib get?
Because osteoarthritis is a progressive, incurable condition, dogs frequently remain on firocoxib for months or years. Responsible chronic NSAID administration requires a structured veterinary monitoring protocol:
| Monitoring Milestone | Recommended Diagnostic Testing | Clinical Rationale & Targets |
|---|---|---|
| Baseline (Pre-Treatment) | Complete Blood Count (CBC), Serum Chemistry (BUN, Creatinine, SDMA, ALT, SAP, Total Bilirubin, Albumin), Urinalysis (with USG). | Establish pre-existing baseline; identify subclinical IRIS Stage 1/2 kidney disease or liver disease before starting. |
| Early Recheck (2 to 4 Weeks) | Focused Chemistry Panel (BUN, Creatinine, ALT, SAP) and Urine Specific Gravity. | Catch acute idiosyncratic hepatic shifts or early renal decompensation before clinical signs manifest. |
| Routine Maintenance (Every 6 Months) | Full Chemistry, CBC, Urinalysis, Physical Examination, Body Weight check. | Standard monitoring for stable adult and senior dogs on chronic daily therapy. |
| High-Risk Patients (Every 3 to 4 Months) | Chemistry, SDMA, Urinalysis, Blood Pressure Measurement. | Indicated for dogs aged 10+, dogs with borderline kidney values, or dogs receiving cardiac medications. |
Multimodal pain management: Reducing NSAID dependence
In modern veterinary medicine, managing canine osteoarthritis rarely relies on an NSAID alone. Integrating multimodal strategies allows clinicians to maintain pain relief while potentially lowering the required NSAID dose:
- Weight optimization: Reducing excess body weight is the single most effective intervention for reducing joint loading and pain.
- Disease-modifying osteoarthritis drugs (DMOADs): Polysulfated glycosaminoglycans (Adequan Canine) support cartilage matrix preservation.
- Piprant alternatives: For dogs with gastrointestinal sensitivity to traditional NSAIDs, EP4 receptor antagonists such as Galliprant for dogs target the specific pain receptor while sparing broader prostanoids.
- Monoclonal antibodies: Monthly bedinvetmab (Librela) injections target Nerve Growth Factor (NGF) to control pain through a non-hepatic, non-renal clearance pathway.
- Comprehensive treatment options: For a complete overview of physical therapy, nutraceuticals, and environmental adaptations, see our clinical guide to dog arthritis treatment options.
What signs mean stop the drug and call your vet now?
Pet owners should be familiar with the early clinical warning signs of NSAID intolerance. If any of the following symptoms appear, discontinue firocoxib immediately and contact your veterinary clinic:
- Vomiting or Hematemesis: Any vomiting, particularly if it contains dark "coffee-ground" material (digested blood) or fresh blood.
- Anorexia or Food Refusal: Skipping a single meal in a dog that normally eats eagerly is a sensitive early indicator of gastric mucosal irritation.
- Melena (Black, Tarry Stools) or Bloody Diarrhea: Indicates upper or lower gastrointestinal hemorrhage.
- Marked Lethargy or Depression: Reluctance to move, excessive sleeping, or unresponsiveness.
- Changes in Drinking and Urination: Sudden increases in water intake (polydipsia) or excessive urination (polyuria), which can signal acute renal decompensation.
- Jaundice (Icterus): Yellowish discoloration of the sclera (whites of the eyes), gums, or inner ear flap skin, indicating acute hepatic injury.
- Incoordination, Tremors, or Stumbling: Weakness or neurological signs.
Frequently asked questions
How long can a dog stay on Previcox or generic firocoxib?
A dog can remain on firocoxib for months to years, provided they undergo regular veterinary examinations and bloodwork monitoring (typically every 6 months for stable dogs, or every 3 to 4 months for senior dogs). The goal of chronic pain management is to maintain comfort and quality of life using the lowest effective dose.
Is firocoxib safer than carprofen for dogs?
Neither drug is universally "safer"; they exhibit different pharmacological and reporting profiles. Firocoxib is highly COX-2 selective (roughly 380-fold), whereas carprofen exhibits balanced or modest COX-2 selectivity. In federal adverse-event data, firocoxib reports feature prominent renal biomarkers in senior dogs alongside upper GI signs, whereas carprofen carries a historical association with rare, idiosyncratic acute hepatocellular toxicities. Individual canine response varies, and some dogs tolerate one NSAID significantly better than another.
Can cats take firocoxib?
No. Firocoxib is strictly contraindicated in cats. Feline physiology cannot safely metabolize canine NSAID dosages, and exposure can trigger fatal acute renal failure and severe gastrointestinal hemorrhage. Cats requiring osteoarthritis pain relief should be evaluated for feline-specific medications such as robenacoxib (Onsior) or frunevetmab (Solensia).
My dog ate several Previcox chewable tablets—what should I do?
Because Previcox and generic firocoxib are flavored chewable tablets, accidental massive overdoses can occur if a dog gains access to the medication bottle. An acute overdose can cause severe gastrointestinal ulceration, intestinal perforation, and acute renal failure. Contact your veterinary clinic, an emergency animal hospital, or a pet poison control center immediately (ASPCA Animal Poison Control Center: 888-426-4435; Pet Poison Helpline: 855-764-7661; consultation fees apply). Inducing vomiting should only be performed under professional veterinary instruction.
Is generic firocoxib as good as brand-name Previcox?
Yes. The FDA-approved generic firocoxib chewable tablets (Firox, the Pegasus/PRN generic, the Felix generic, and Firodyl) are approved via the ANADA pathway. They contain the identical active drug molecule at the same strength and have demonstrated blood-level bioequivalence in live dogs, ensuring the same clinical efficacy and safety profile at a lower cost.
What bloodwork should my dog get while on firocoxib long-term?
Dogs on chronic firocoxib therapy should receive a baseline blood chemistry panel (evaluating BUN, creatinine, SDMA, ALT, SAP, total bilirubin, and albumin), a complete blood count (checking for anemia), and a urinalysis (measuring urine concentration) before starting. Bloodwork should be repeated 2 to 4 weeks after starting therapy, and every 6 months thereafter for routine maintenance.
Sources
- Freedom of Information Summary, NADA 141-230, PREVICOX Chewable Tablets (firocoxib) — FDA Center for Veterinary Medicine. Primary pioneer approval document detailing field-trial adverse reactions (Table 5) and target animal safety findings.
- New Animal Drugs; Approval of New Animal Drug Applications (August 16, 2023) — Federal Register. Official notice documenting the Pegasus Laboratories generic firocoxib approval (ANADA 200-751, June 22, 2023).
- New Animal Drugs; Approval of New Animal Drug Applications (September 29, 2022) — Federal Register. Official notice documenting the Firox approval (Norbrook, ANADA 200-722, March 28, 2022).
- New Animal Drugs; Approval of New Animal Drug Applications (December 6, 2023) — Federal Register. Official notice documenting the Felix Pharmaceuticals (ANADA 200-755) and Firodyl (ANADA 200-756) approvals, both August 3, 2023.
- FOI Summary for the Original Approval of ANADA 200-751, Firocoxib Chewable Tablets for Dogs — PRN Pharmacal / FDA CVM. Bioequivalence study documentation establishing generic pharmacokinetic equivalence to Previcox.
- Evaluation of the adverse effects of oral firocoxib in healthy dogs — PMC / PubMed Central. Controlled study evaluating gastrointestinal and biochemical safety parameters of oral firocoxib in canines.
- The effects of firocoxib (Previcox) in geriatric dogs over time — PubMed. Peer-reviewed clinical evaluation of long-term firocoxib administration and tolerability in geriatric canine populations.
- PREVICOX (firocoxib) Chewable Tablets Product Information — Boehringer Ingelheim Animal Health. Prescribing information, labeled indications, and safety warnings for pioneer firocoxib.
- FDA Animal Drugs @ FDA Database — FDA Center for Veterinary Medicine. Regulatory approval records for veterinary pharmaceuticals.
